NLRP3 inflammasome and pathobiology in AMD

Journal of Clinical Medicine

Volumn 4, Issue 1, 2015, Pages 172-192

  Celkova, Lucia ^a   Doyle, Sarah L ^b   Campbell, Matthew ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Age related macular degeneration; Autophagy; Choroidal neovascularization; Geographic atrophy; IL 18; NLRP3 inflammasome; Pyroptosis; Retinal pigment epithelium

Indexed keywords

CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CRYOPYRIN; CYTOKINE; DICER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUCINE RICH REPEAT KINASE 2; LIPOFUSCIN; MULTIPROTEIN COMPLEX; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; AUTOPHAGY; BLINDNESS; CELL DEATH; CYTOTOXICITY; DISEASE COURSE; GEOGRAPHIC ATROPHY; HUMAN; OXIDATIVE STRESS; PHOTORECEPTOR; PIGMENT EPITHELIUM; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

EID: 84957091470     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4010172     Document Type: Review

References (112)

1. Fritsche, L.G.; Chen, W.; Schu, M.; Yaspan, B.L.; Yu, Y.; Thorleifsson, G.; Zack, D.J.; Arakawa, S.; Cipriani, V.; Ripke, S., et al. Seven new loci associated with age-related macular degeneration. Nat. Genet. 2013, 45, 433–439.
2. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-related eye disease study report number 3. Ophthalmology 2000, 107, 2224–2232.
3. Clemons, T.E.; Milton, R.C.; Klein, R.; Seddon, J.M.; Ferris, F.L., III. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS report no. 19. Ophthalmology 2005, 112, 533–539.
4. Dasari, B.; Prasanthi, J.R.; Marwarha, G.; Singh, B.B.; Ghribi, O. Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina. BMC Ophthalmol. 2011, 11, doi:10.1186/1471-2415-11-22.
5. Parekh, N.; Voland, R.P.; Moeller, S.M.; Blodi, B.A.; Ritenbaugh, C.; Chappell, R.J.; Wallace, R.B.; Mares, J.A. Association between dietary fat intake and age-related macular degeneration in the carotenoids in age-related eye disease study (CAREDS): An ancillary study of the women’s health initiative. Arch. Ophthalmol. 2009, 127, 1483–1493.
6. Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358, 2606–2617.
7. Sui, G.Y.; Liu, G.C.; Liu, G.Y.; Gao, Y.Y.; Deng, Y.; Wang, W.Y.; Tong, S.H.; Wang, L. Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br. J. Ophthalmol. 2013, 97, 389–394.
8. Millen, A.E.; Voland, R.; Sondel, S.A.; Parekh, N.; Horst, R.L.; Wallace, R.B.; Hageman, G.S.; Chappell, R.; Blodi, B.A.; Klein, M.L., et al. Vitamin D status and early age-related macular degeneration in postmenopausal women. Arch. Ophthalmol. 2011, 129, 481–489.
9. Nita, M.; Grzybowski, A.; Ascaso, F.J.; Huerva, V. Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). Med. Inflamm. 2014, 2014, doi:10.1155/2014/930671.
10. Whitcup, S.M.; Sodhi, A.; Atkinson, J.P.; Holers, V.M.; Sinha, D.; Rohrer, B.; Dick, A.D. The role of the immune response in age-related macular degeneration. Int. J. Inflamm. 2013, 2013, doi:10.1155/2013/348092.
11. Mullins, R.F.; Russell, S.R.; Anderson, D.H.; Hageman, G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000, 14, 835–846.
12. Johnson, L.V.; Leitner, W.P.; Rivest, A.J.; Staples, M.K.; Radeke, M.J.; Anderson, D.H. The Alzheimer’s a beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl. Acad. Sci. USA 2002, 99, 11830–11835.
13. Wang, L.; Clark, M.E.; Crossman, D.K.; Kojima, K.; Messinger, J.D.; Mobley, J.A.; Curcio, C.A. Abundant lipid and protein components of drusen. PLoS One 2010, 5, e10329.
14. Crabb, J.W.; Miyagi, M.; Gu, X.; Shadrach, K.; West, K.A.; Sakaguchi, H.; Kamei, M.; Hasan, A.; Yan, L.; Rayborn, M.E., et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 2002, 99, 14682–14687.
15. Sparrow, J.R.; Boulton, M. RPE lipofuscin and its role in retinal pathobiology. Exp.Eye Res. 2005, 80, 595–606.
16. Pascolini, D.; Mariotti, S.P. Global estimates of visual impairment: 2010. Br. J. Ophthalmol. 2012, 96, 614–618.
17. Access Economics. The Global Economic Cost of Visual Impairment. Available online: http://www.icoph.org/resources/146/The-Global-Economic-Cost-of-Visual-Impairment.html (accessed on 17 September 2014).
18. Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health 2014, 2, doi:10.1016/S2214-109X(13)70145-1.
19. Bright Focus Foundation. Available online: http://www.brightfocus.org/macular/about/understanding/ facts.html(accessed on 17 September 2014).
20. National Council for the Blind of Ireland. The Cost of Blindness in the Republic of Ireland 2010–2020. Available online: https://www.ncbi.ie/sites/default/files/cost_of_blindness_pdf_ nov_2012.pdf(accessed on 17 September 2014).
21. National Council for the Blind of Ireland. The Economic Impact of Vision Impairment and Blindness in the Republic of Ireland. Available online: http://www.ncbi.ie/files/Cost_of_ Sight_Loss_Full_Report_July_2011.pdf (accessed on 18 September 2014).
22. Schroder, K.; Tschopp, J. The inflammasomes. Cell 2010, 140, 821–832.
23. Dowling, J.K.; O’Neill, L.A. Biochemical regulation of the inflammasome. Crit. Rev. Biochem. Mol. Biol. 2012, 47, 424–443.
24. Mariathasan, S.; Weiss, D.S.; Newton, K.; McBride, J.; O’Rourke, K.; Roose-Girma, M.; Lee, W.P.; Weinrauch, Y.; Monack, D.M.; Dixit, V.M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440, 228–232.
25. Yamasaki, K.; Muto, J.; Taylor, K.R.; Cogen, A.L.; Audish, D.; Bertin, J.; Grant, E.P.; Coyle, A.J.; Misaghi, A.; Hoffman, H.M., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J. Biol. Chem. 2009, 284, 12762–12771.
26. Halle, A.; Hornung, V.; Petzold, G.C.; Stewart, C.R.; Monks, B.G.; Reinheckel, T.; Fitzgerald, K.A.; Latz, E.; Moore, K.J.; Golenbock, D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9, 857–865.
27. Zhou, R.; Tardivel, A.; Thorens, B.; Choi, I.; Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11, 136–140.
28. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440, 237–241.
29. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nunez, G.; Schnurr, M., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464, 1357–1361.
30. Compan, V.; Baroja-Mazo, A.; Lopez-Castejon, G.; Gomez, A.I.; Martinez, C.M.; Angosto, D.; Montero, M.T.; Herranz, A.S.; Bazan, E.; Reimers, D., et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 2012, 37, 487–500.
31. Rajamaki, K.; Nordstrom, T.; Nurmi, K.; Akerman, K.E.; Kovanen, P.T.; Oorni, K.; Eklund, K.K. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 2013, 288, 13410–13419.
32. Babelova, A.; Moreth, K.; Tsalastra-Greul, W.; Zeng-Brouwers, J.; Eickelberg, O.; Young, M.F.; Bruckner, P.; Pfeilschifter, J.; Schaefer, R.M.; Grone, H.J., et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009, 284, 24035–24048.
33. Eisenbarth, S.C.; Colegio, O.R.; O’Connor, W.; Sutterwala, F.S.; Flavell, R.A. Crucial role for the NALP3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453, 1122–1126.
34. Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E.O.; Kono, H.; Rock, K.L.; Fitzgerald, K.A.; Latz, E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9, 847–856.
35. Dostert, C.; Petrilli, V.; van Bruggen, R.; Steele, C.; Mossman, B.T.; Tschopp, J. Innate immune activation through NALP3 inflammasome sensing of asbestos and silica. Science 2008, 320, 674–677.
36. Yazdi, A.S.; Guarda, G.; Riteau, N.; Drexler, S.K.; Tardivel, A.; Couillin, I.; Tschopp, J. Nanoparticles activate the nlr pyrin domain containing 3 (NLRP3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc. Natl. Acad. Sci. USA 2010, 107, 19449–19454.
37. Kahlenberg, J.M.; Dubyak, G.R. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. 2004, 286, C1100–C1108.
38. Munoz-Planillo, R.; Kuffa, P.; Martinez-Colon, G.; Smith, B.L.; Rajendiran, T.M.; Nunez, G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38, 1142–1153.
39. Petrilli, V.; Papin, S.; Dostert, C.; Mayor, A.; Martinon, F.; Tschopp, J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007, 14, 1583–1589.
40. Murakami, T.; Ockinger, J.; Yu, J.; Byles, V.; McColl, A.; Hofer, A.M.; Horng, T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA 2012, 109, 11282–11287.
41. Cruz, C.M.; Rinna, A.; Forman, H.J.; Ventura, A.L.; Persechini, P.M.; Ojcius, D.M. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem. 2007, 282, 2871–2879.
42. Shimada, K.; Crother, T.R.; Karlin, J.; Dagvadorj, J.; Chiba, N.; Chen, S.; Ramanujan, V.K.; Wolf, A.J.; Vergnes, L.; Ojcius, D.M., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36, 401–414.
43. Lopez-Castejon, G.; Luheshi, N.M.; Compan, V.; High, S.; Whitehead, R.C.; Flitsch, S.; Kirov, A.; Prudovsky, I.; Swanton, E.; Brough, D. Deubiquitinases regulate the activity of caspase-1 and interleukin-1beta secretion via assembly of the inflammasome. J. Biol. Chem. 2013, 288, 2721–2733.
44. Hoegen, T.; Tremel, N.; Klein, M.; Angele, B.; Wagner, H.; Kirschning, C.; Pfister, H.W.; Fontana, A.; Hammerschmidt, S.; Koedel, U. The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J. Immunol. 2011, 187, 5440–5451.
45. Bauernfeind, F.G.; Horvath, G.; Stutz, A.; Alnemri, E.S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.; Monks, B.G.; Fitzgerald, K.A., et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183, 787–791.
46. Doyle, S.L.; Campbell, M.; Ozaki, E.; Salomon, R.G.; Mori, A.; Kenna, P.F.; Farrar, G.J.; Kiang, A.S.; Humphries, M.M.; Lavelle, E.C., et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 2012, 18, 791–798.
47. Tseng, W.A.; Thein, T.; Kinnunen, K.; Lashkari, K.; Gregory, M.S.; D’Amore, P.A.; Ksander, B.R. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: Implications for age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013, 54, 110–120.
48. Kauppinen, A.; Niskanen, H.; Suuronen, T.; Kinnunen, K.; Salminen, A.; Kaarniranta, K. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells—Implications for age-related macular degeneration (AMD). Immunol. Lett. 2012, 147, 29–33.
49. Tarallo, V.; Hirano, Y.; Gelfand, B.D.; Dridi, S.; Kerur, N.; Kim, Y.; Cho, W.G.; Kaneko, H.; Fowler, B.J.; Bogdanovich, S., et al. Dicer1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MYD88. Cell 2012, 149, 847–859.
50. Liu, R.T.; Gao, J.; Cao, S.; Sandhu, N.; Cui, J.Z.; Chou, C.L.; Fang, E.; Matsubara, J.A. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: Implications for inflammasome activation in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013, 54, 2225–2237.
51. Anderson, O.A.; Finkelstein, A.; Shima, D.T. A2E induces IL-1ss production in retinal pigment epithelial cells via the NLRP3 inflammasome. PLoS One 2013, 8, e67263.
52. Marneros, A.G. NLRP3 inflammasome blockade inhibits VEGF-a-induced age-related macular degeneration. Cell Rep. 2013, 4, 945–958.
53. Puren, A.J.; Fantuzzi, G.; Dinarello, C.A. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. USA 1999, 96, 2256–2261.
54. Hiscott, J.; Marois, J.; Garoufalis, J.; D’Addario, M.; Roulston, A.; Kwan, I.; Pepin, N.; Lacoste, J.; Nguyen, H.; Bensi, G., et al. Characterization of a functional NF-κB site in the human interleukin 1 beta promoter: Evidence for a positive autoregulatory loop. Mol. Cell. Biol. 1993, 13, 6231–6240.
55. Dinarello, C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 2006, 83 (Suppl. S2), 447–455.
56. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Ann. Rev. Immunol. 2009, 27, 519–550.
57. Garlanda, C.; Dinarello, C.A.; Mantovani, A. The interleukin-1 family: Back to the future. Immunity 2013, 39, 1003–1018.
58. Ben-Av, P.; Crofford, L.J.; Wilder, R.L.; Hla, T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin e and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995, 372, 83–87.
59. El Awad, B.; Kreft, B.; Wolber, E.M.; Hellwig-Burgel, T.; Metzen, E.; Fandrey, J.; Jelkmann, W. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 2000, 58, 43–50.
60. Jung, Y.D.; Liu, W.; Reinmuth, N.; Ahmad, S.A.; Fan, F.; Gallick, G.E.; Ellis, L.M. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the p38 mitogen-activated protein kinase pathway. Angiogenesis 2001, 4, 155–162.
61. Voronov, E.; Shouval, D.S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C.A.; Apte, R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 2645–2650.
62. Yano, S.; Nokihara, H.; Yamamoto, A.; Goto, H.; Ogawa, H.; Kanematsu, T.; Miki, T.; Uehara, H.; Saijo, Y.; Nukiwa, T., et al. Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in scid mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. Cancer Sci. 2003, 94, 244–252.
63. Sola-Villa, D.; Camacho, M.; Sola, R.; Soler, M.; Diaz, J.M.; Vila, L. IL-1beta induces VEGF, independently of PGE2 induction, mainly through the pi3-k/mtor pathway in renal mesangial cells. Kidney Int. 2006, 70, 1935–1941.
64. Nakanishi, K.; Yoshimoto, T.; Tsutsui, H.; Okamura, H. Interleukin-L8 regulates both TH1 and TH2 responses. Ann. Rev. Immunol. 2001, 19, 423–474.
65. Nakanishi, K.; Yoshimoto, T.; Tsutsui, H.; Okamura, H. Interleukin-18 is a unique cytokine that stimulates both TH1 and TH2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001, 12, 53–72.
66. Boraschi, D.; Dinarello, C.A. IL-18 in autoimmunity: Review. Eur. Cytokine Netw. 2006, 17, 224–252.
67. Dinarello, C.A.; Novick, D.; Kim, S.; Kaplanski, G. Interleukin-L8 and IL-18 binding protein. Front. Immunol. 2013, 4, 1–10.
68. Bamias, G.; Corridoni, D.; Pizarro, T.T.; Cominelli, F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012, 59, 451–459.
69. Bian, Z.M.; Elner, S.G.; Yoshida, A.; Kunkel, S.L.; Su, J.; Elner, V.M. Activation of p38, ERK1/2 and NIK pathways is required for IL-1beta and TNF-alpha-induced chemokine expression in human retinal pigment epithelial cells. Exp. Eye Res. 2001, 73, 111–121.
70. Abe, T.; Sugano, E.; Saigo, Y.; Tamai, M. Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): Aberrant expression of junctional complex molecules. Investig. Ophthalmol. Vis. Sci. 2003, 44, 4097–4104.
71. Peng, S.; Gan, G.; Rao, V.S.; Adelman, R.A.; Rizzolo, L.J. Effects of proinflammatory cytokines on the claudin-19 rich tight junctions of human retinal pigment epithelium. Investig. Ophthalmol. Vis. Sci. 2012, 53, 5016–5028.
72. Olson, J.L.; Courtney, R.J.; Rouhani, B.; Mandava, N.; Dinarello, C.A. Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocul. Immunol. Inflamm. 2009, 17, 195–200.
73. Doyle, S.L.; Ozaki, E.; Brennan, K.; Humphries, M.M.; Mulfaul, K.; Keaney, J.; Kenna, P.F.; Maminishkis, A.; Kiang, A.S.; Saunders, S.P., et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci. Transl. Med. 2014, 6, doi:10.1126/scitranslmed.3007616.
74. Doyle, S.L.; Adamson, P.; Lopez, F.J.; Humphries, P.; Campbell, M. Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat. Med. 2014, 20, 1376–1377.
75. Shen, J.; Choy, D.F.; Yoshida, T.; Iwase, T.; Hafiz, G.; Xie, B.; Hackett, S.F.; Arron, J.R.; Campochiaro, P.A. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: Reciprocal suppression with vegf. J. Cell. Physiol. 2014, 229, 974–983.
76. Miao, E.A.; Leaf, I.A.; Treuting, P.M.; Mao, D.P.; Dors, M.; Sarkar, A.; Warren, S.E.; Wewers, M.D.; Aderem, A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 2010, 11, 1136–1142.
77. Bergsbaken, T.; Fink, S.L.; Cookson, B.T. Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7, 99–109.
78. Fink, S.L.; Cookson, B.T. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 2005, 73, 1907–1916.
79. Holler, N.; Zaru, R.; Micheau, O.; Thome, M.; Attinger, A.; Valitutti, S.; Bodmer, J.L.; Schneider, P.; Seed, B.; Tschopp, J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase rip as effector molecule. Nat. Immunol. 2000, 1, 489–495.
80. Vandenabeele, P.; Galluzzi, L.; Vanden Berghe, T.; Kroemer, G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 2010, 11, 700–714.
81. Murakami, Y.; Matsumoto, H.; Roh, M.; Giani, A.; Kataoka, K.; Morizane, Y.; Kayama, M.; Thanos, A.; Nakatake, S.; Notomi, S., et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and damp-mediated inflammation in dsrna-induced retinal degeneration. Cell Death Differ. 2014, 21, 270–277.
82. Shelley, E.J.; Madigan, M.C.; Natoli, R.; Penfold, P.L.; Provis, J.M. Cone degeneration in aging and age-related macular degeneration. Arch. Ophthalmol. 2009, 127, 483–492.
83. Kaneko, H.; Dridi, S.; Tarallo, V.; Gelfand, B.D.; Fowler, B.J.; Cho, W.G.; Kleinman, M.E.; Ponicsan, S.L.; Hauswirth, W.W.; Chiodo, V.A., et al. Dicer1 deficit induces alu rna toxicity in age-related macular degeneration. Nature 2011, 471, 325–330.
84. Jones, S.A.; Mills, K.H.; Harris, J. Autophagy and inflammatory diseases. Immunol. Cell Biol. 2013, 91, 250–258.
85. Harris, J. Autophagy and IL-1 family cytokines. Front. Immunol. 2013, 4, doi:10.3389/fimmu.2013.00083.
86. Zhou, R.; Yazdi, A.S.; Menu, P.; Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469, 221–225.
87. Nakahira, K.; Haspel, J.A.; Rathinam, V.A.; Lee, S.J.; Dolinay, T.; Lam, H.C.; Englert, J.A.; Rabinovitch, M.; Cernadas, M.; Kim, H.P., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011, 12, 222–230.
88. Harris, J.; Hartman, M.; Roche, C.; Zeng, S.G.; O’Shea, A.; Sharp, F.A.; Lambe, E.M.; Creagh, E.M.; Golenbock, D.T.; Tschopp, J., et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J. Biol. Chem. 2011, 286, 9587–9597.
89. Shi, C.S.; Shenderov, K.; Huang, N.N.; Kabat, J.; Abu-Asab, M.; Fitzgerald, K.A.; Sher, A.; Kehrl, J.H. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 2012, 13, 255–263.
90. Byrne, B.G.; Dubuisson, J.F.; Joshi, A.D.; Persson, J.J.; Swanson, M.S. Inflammasome components coordinate autophagy and pyroptosis as macrophage responses to infection. MBIO 2013, 4, doi:10.1128/mBio.00620-12.
91. Wang, A.L.; Lukas, T.J.; Yuan, M.; Du, N.; Tso, M.O.; Neufeld, A.H. Autophagy and exosomes in the aged retinal pigment epithelium: Possible relevance to drusen formation and age-related macular degeneration. PLoS One 2009, 4, e4160.
92. Kim, J.Y.; Zhao, H.; Martinez, J.; Doggett, T.A.; Kolesnikov, A.V.; Tang, P.H.; Ablonczy, Z.; Chan, C.C.; Zhou, Z.; Green, D.R., et al. Noncanonical autophagy promotes the visual cycle. Cell 2013, 154, 365–376.
93. Martin, D.F.; Maguire, M.G.; Ying, G.S.; Grunwald, J.E.; Fine, S.L.; Jaffe, G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364, 1897–1908.
94. He, L.; Marneros, A.G. Macrophages are essential for the early wound healing response and the formation of a fibrovascular scar. Am. J. Pathol. 2013, 182, 2407–2417.
95. Dupaul-Chicoine, J.; Yeretssian, G.; Doiron, K.; Bergstrom, K.S.; McIntire, C.R.; LeBlanc, P.M.; Meunier, C.; Turbide, C.; Gros, P.; Beauchemin, N., et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32, 367–378.
96. Allen, I.C.; TeKippe, E.M.; Woodford, R.M.; Uronis, J.M.; Holl, E.K.; Rogers, A.B.; Herfarth, H.H.; Jobin, C.; Ting, J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207, 1045–1056.
97. Zaki, M.H.; Boyd, K.L.; Vogel, P.; Kastan, M.B.; Lamkanfi, M.; Kanneganti, T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32, 379–391.
98. Zaki, M.H.; Vogel, P.; Body-Malapel, M.; Lamkanfi, M.; Kanneganti, T.D. IL-18 production downstream of the NLRP3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 2010, 185, 4912–4920.
99. Qiao, H.; Sonoda, K.H.; Sassa, Y.; Hisatomi, T.; Yoshikawa, H.; Ikeda, Y.; Murata, T.; Akira, S.; Ishibashi, T. Abnormal retinal vascular development in IL-18 knockout mice. Lab. Investig. J. Tech. Methods Pathol. 2004, 84, 973–980.
100. Qiao, H.; Sonoda, K.H.; Ikeda, Y.; Yoshimura, T.; Hijioka, K.; Jo, Y.J.; Sassa, Y.; Tsutsumi-Miyahara, C.; Hata, Y.; Akira, S., et al. Interleukin-L8 regulates pathological intraocular neovascularization. J. Leukoc. Biol. 2007, 81, 1012–1021.
101. Mallat, Z.; Silvestre, J.S.; Le Ricousse-Roussanne, S.; Lecomte-Raclet, L.; Corbaz, A.; Clergue, M.; Duriez, M.; Barateau, V.; Akira, S.; Tedgui, A., et al. Interleukin-L8/interleukin-L8 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb. Circ. Res. 2002, 91, 441–448.
102. Coughlin, C.M.; Salhany, K.E.; Wysocka, M.; Aruga, E.; Kurzawa, H.; Chang, A.E.; Hunter, C.A.; Fox, J.C.; Trinchieri, G.; Lee, W.M. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Investig. 1998, 101, 1441–1452.
103. Kerur, N.; Hirano, Y.; Tarallo, V.; Fowler, B.J.; Bastos-Carvalho, A.; Yasuma, T.; Yasuma, R.; Kim, Y.; Hinton, D.R.; Kirschning, C.J., et al. TLR-independent and P2X7-dependent signaling mediate alu rna-induced NLRP3 inflammasome activation in geographic atrophy. Investig. Ophthalmol. Vis. Sci. 2013, 54, 7395–7401.
104. Kindzelskii, A.L.; Elner, V.M.; Elner, S.G.; Yang, D.; Hughes, B.A.; Petty, H.R. Toll-like receptor 4 (TLR4) of retinal pigment epithelial cells participates in transmembrane signaling in response to photoreceptor outer segments. J. Gen. Physiol. 2004, 124, 139–149.
105. Fernandes-Alnemri, T.; Wu, J.; Yu, J.W.; Datta, P.; Miller, B.; Jankowski, W.; Rosenberg, S.; Zhang, J.; Alnemri, E.S. The pyroptosome: A supramolecular assembly of Asc dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007, 14, 1590–1604.
106. Lu, A.; Magupalli, V.G.; Ruan, J.; Yin, Q.; Atianand, M.K.; Vos, M.R.; Schroder, G.F.; Fitzgerald, K.A.; Wu, H.; Egelman, E.H. Unified polymerization mechanism for the assembly of asc-dependent inflammasomes. Cell 2014, 156, 1193–1206.
107. Cai, X.; Chen, J.; Xu, H.; Liu, S.; Jiang, Q.X.; Halfmann, R.; Chen, Z.J. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 2014, 156, 1207–1222.
108. Grunwald, G.B. Structure and function of the retinal pigment epithelium. In Duane’s Ophthalmology, 6th ed.; Tasman, W., Jaeger, E.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, Pennsylvania, USA, 2006.
109. O’Neill, L.A.; Bowie, A.G. The family of five: Tir-domain-containing adaptors in toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7, 353–364.
110. Fowler, B.J.; Gelfand, B.D.; Kim, Y.; Kerur, N.; Tarallo, V.; Hirano, Y.; Amarnath, S.; Fowler, D.H.; Radwan, M.; Young, M.T., et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 2014, 346, 1000–1003.
111. Ablonczy, Z.; Dahrouj, M.; Marneros, A.G. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J. 2014, 28, 2369–2379.
112. Liu, R.T.; Wang, A.; To, E.; Gao, J.; Cao, S.; Cui, J.Z.; Matsubara, J.A. Vinpocetine inhibits amyloid-beta induced activation of NF-kappaB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp. Eye Res. 2014, 127C, 49–58.